<DOC>
	<DOC>NCT02871037</DOC>
	<brief_summary>The current study is the first clinical trial proposed with PF-05221304. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single and repeated doses of PF-05221304 to healthy adult subjects. The study may also evaluate effect of food on PK of PF-05221304.</brief_summary>
	<brief_title>Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy males and female of nonchildbearing potential; Body Mass Index 17.530.5 kg/m2; Body weight &gt;50 kg; Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>